ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / NSPR / options
PMI (48) RVP (31) PLRZ (34) MODD (33) ⌘ Pro Terminal →

InspireMD Inc. (NSPR) Options Positioning, Max Pain & Unusual Sweeps

$0.54 +19.78% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.56

InspireMD Inc. (NSPR) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $20.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on NSPR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is NSPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, InspireMD Inc. (NASDAQ: NSPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $0.54 (+19.78% 1D, market cap $20.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NSPR ranks #735 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does NSPR compare to PMI and RVP in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), NSPR carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 29.5%, and ROIC of -35.0%. By comparison, PMI (Picard Medical Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $20.5M) and RVP (Retractable Technologies Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -23.3%, cap $16.9M). Among the 5-stock peer group, NSPR leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for NSPR?
▼

Per NSPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001433607), InspireMD Inc. generated $9.0M in revenue (+28.1% YoY), -$48.8M in net income, and -$36.8M in free cash flow against $69.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.56 (+3.37%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510032
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (6)Whales (6)SEC (8)Macro (7)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-11.1% Base Target
$3 Bull$0 Base$0 Bear
📬 FREE NSPR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NSPR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY NSPR SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (22% of score)

FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 30.2 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
24
Grade E$0.50-12% Next Q
Q2 (-2Q)
27
Grade E$0.44+4.5% Next Q
Q3 (-1Q)
29
Grade E$0.46+17.4% Next Q
Current
32
Grade E$0.54-9.2% Hist 90D α
Trajectory: E (24) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NSPR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NSPR currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.65) and Max Pain ($0.57) forces dealer call-delta covering toward $2.52.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NSPR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NSPR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 32%NO 68%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (NSPR)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for NSPR.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NSPR)

  • ✓Walkthrough of NSPR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
NSPR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -53.85%▼ DESCENDING CHANNEL
2026-11-03O $0.45H $0.54L $0.45C $0.54VOL 478.7K
RES: $0.79SUP: $0.42SMA50: $0.65SMA200: $1.06
$2.09$1.64$1.19$0.74$0.29RES $0.79SUP $0.42$0.542026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NSPR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NSPR Butterfly Map → + Track NSPR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +28.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on NSPR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NSPR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NSPR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NSPR)

Health Care Rank #735 of 1016 ⚔️ PMI vs NSPR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NSPR vs. PMI, RVP, PLRZ, MODD)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, InspireMD Inc. (NSPR) ranks #735 by composite RQD confidence (32/100, grade E) and #827 by equity capitalization ($20.9M). Within this direct 5-issuer industry benchmark cohort, NSPR leads on earnings valuation at N/A trailing P/E, while RVP leads on capital efficiency and profitability with -23.3% ROIC and 0.1% gross margin. PMI currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with NSPR at 32/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
NSPR ACTIVE
InspireMD Inc.
E 32/100 — 29.5% -35.0% +19.78% $20.9M Benchmark Subject
PMI
Picard Medical Inc.
D 48/100 — — — +2.75% $20.5M /pmi-vs-nspr →
RVP
Retractable Technologies Inc.
E 31/100 — 0.1% -23.3% +0.18% $16.9M /rvp-vs-nspr →
PLRZ
Polyrizon Ltd.
E 34/100 — — -25.1% +4.74% $26.1M /plrz-vs-nspr →
MODD
Modular Medical Inc.
E 33/100 — — -35.0% +4.65% $16.3M /modd-vs-nspr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001433607

In its most recent audited fiscal period (FY2025, filed 2025-12-31), InspireMD Inc. (NSPR) reported GAAP revenue of $9.0M (+28.1% vs. FY2024 revenue of $7.0M , and +44.7% cumulative change since FY2023) , GAAP net income of -$48.8M, operating cash flow of -$35.1M, and free cash flow of -$36.8M (-58.0% YoY). On the balance sheet, NSPR closed FY2025 with $69.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $9.0M -$48.8M -$35.1M -$36.8M $69.4M —
FY2024 (FY) 2024-12-31 $7.0M -$32.0M -$21.9M -$23.3M $46.8M —
FY2023 (FY) 2023-12-31 $6.2M -$19.9M -$16.4M -$16.4M — —

3. NSPR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NSPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, InspireMD Inc. (NASDAQ: NSPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $0.54 (+19.78% 1D, market cap $20.9M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NSPR ranks #735 in composite RQD confidence.

How does NSPR compare to PMI and RVP in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), NSPR carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of 29.5%, and ROIC of -35.0%. By comparison, PMI (Picard Medical Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC —, cap $20.5M) and RVP (Retractable Technologies Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -23.3%, cap $16.9M). Among the 5-stock peer group, NSPR leads on earnings multiple (N/A) while RVP leads on capital efficiency (-23.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NSPR?

Per NSPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001433607), InspireMD Inc. generated $9.0M in revenue (+28.1% YoY), -$48.8M in net income, and -$36.8M in free cash flow against $69.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NSPR trading relative to its 50-day, 200-day, and 52-week technical levels?

NSPR last traded at $0.54 (+19.78% on volume of 650,772 shares), positioning the stock -16.92% below its 50-day simple moving average ($0.65) and -49.06% below its 200-day simple moving average ($1.06). Across its 52-week range of $0.43 to $2.40, NSPR sits at the 5.6% percentile with a 14-day RSI of 30.2 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.00 to $0.61).

Direct Sub-Reports: NSPR RQD Cockpit NSPR 12M Forecast NSPR Earnings & Move NSPR Dividends & DRIP NSPR Insiders & 13F NSPR Whale Options NSPR Profit Sankey NSPR News & Why
ROARABLE RATING BRIEF • RQD 32/100 (E) ✓ SEC XBRL & RQD VERIFIED

NSPR — InspireMD Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

InspireMD Inc. (NSPR) earns a live Roarable RQD composite score of 32/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.54 (+19.78% 1D, market capitalization $20.9M).

  • Fundamental Cash Engine (6/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 29.5%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (8/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

InspireMD Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical/Dental Instruments industry.. Revenue is reported in the financials at $9.0M for FY 2025.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), InspireMD Inc. (NSPR) reported $9.0M in annual revenue (up from $7.0M in FY2024, +28.1% YoY) and -$48.8M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($6.2M revenue, -$19.9M net income) through FY2025, NSPR scaled operating cash flow to -$35.1M and free cash flow to -$36.8M, backed by $69.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 32/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 6/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $0.43 – $2.40 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context provided is the Health Care / Medical/Dental Instruments classification and the Roarable RQD beta reading of 1.0.

  • Key Question #1: Can NSPR sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $9.0M and free cash flow of -$36.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is NSPR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

NSPR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for InspireMD Inc. (NSPR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to NSPR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

NSPR Bull vs. Bear Conversation Board — What's Your Call at $0.54?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON NSPR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on NSPR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $0.59 (+31.1%)
📌 Pinned Debate

Revenue grew from $6.2M in FY 2023 to $9.0M in FY 2025, and the stock has reclaimed the $0.50 level per recent market wire coverage.

Don't sleep on NSPR's setup in Health Care. Revenue grew from $6.2M in FY 2023 to $9.0M in FY 2025, and the stock has reclaimed the $0.50 level per recent market wire coverage.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (32/100) backs up the fundamental quality.

CapAlloc_Nerd 🐂 BULL

@RedlineAuditor Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Medical/Dental Instruments. If gross margin (29.5%) holds, EPS grows into the multiple faster than bears think.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $0.35 (-22.2%)
Spot @ $0.45

Operating losses widened to -$49.6M in FY 2025 with ROIC at -35% and FCF at -$36.8M against only $8.9M of cash.

Here is the bear case nobody on the bull side wants to address on NSPR: Operating losses widened to -$49.6M in FY 2025 with ROIC at -35% and FCF at -$36.8M against only $8.9M of cash.. At current EV/EBITDA multiples, even a small guidance miss in Medical/Dental Instruments triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%